高类风湿因子水平患者接受TNF抑制剂治疗的临床与临床前结局:系统综述
本系统综述纳入21项研究,其中18项报告了8910例接受TNF抑制剂治疗的类风湿关节炎患者的疗效与有效性结局。结果显示,高类风湿因子水平患者接受无Fc段TNF抑制剂时,临床疾病活动指数、简化疾病活动指数、DAS28-CRP或DAS28-ESR及布尔缓解等临床终点与低类风湿因子水平患者相似或略优。
要点
- 高类风湿因子水平患者使用无Fc段TNF抑制剂时临床缓解结局相似或略优于低类风湿因子水平者。
- 类风湿因子可与含Fc段生物制剂结合形成免疫复合物,可能降低药物可用性并减弱治疗反应。
- 系统综述提示无Fc段TNF抑制剂可能对高类风湿因子水平类风湿关节炎患者有一定优势。
核心结论
- 无Fc段TNF抑制剂可能为高类风湿因子水平的类风湿关节炎患者提供一定优势。
研究设计与样本
- 系统综述检索MEDLINE、Embase和Cochrane CENTRAL至2025年1月并在2025年7月更新。
- 共纳入21项研究,其中1项报告临床与临床前数据,3项报告临床前数据,18项报告8910例接受TNF抑制剂治疗患者的疗效与有效性结局。
主要发现
- 高类风湿因子水平患者接受无Fc段TNF抑制剂时,临床疾病活动指数、简化疾病活动指数、DAS28-CRP或DAS28-ESR及布尔缓解等临床终点与低类风湿因子水平患者相似或略优。
- 类风湿因子可与免疫球蛋白G1的Fc段及含Fc段生物制剂的Fc区结合形成免疫复合物,随后被巨噬细胞清除,可能导致药物可用性降低和治疗反应减弱。
临床怎么用
- 对高类风湿因子水平的类风湿关节炎患者,选择无Fc段TNF抑制剂可能有助于改善临床结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Rheumatoid factor (RF) binds to the fragment crystallisable (Fc) portion of immunoglobulin G1 and can also bind to the Fc region of biologic agents, forming immune complexes that are subsequently cleared by macrophages, contributing to reduced drug availability and diminished therapeutic response. In this systematic review, we examined the binding mechanism and impact of RF on tumour necrosis factor inhibitors (TNFis) with and without an Fc portion, along with the impact of RF levels on drug concentration and clinical outcomes in patients with rheumatoid arthritis (RA). METHODS: Searches were carried out in MEDLINE, Embase, and Cochrane CENTRAL up to January 2025 and updated in July 2025. Abstracts and full texts were screened, and discrepancies were resolved by consensus. Studies that included at least 1 group of adult patients with high RF treated with TNFis (with or without an Fc region) with outcomes of interest were considered for inclusion. RESULTS: Of the 21 studies included, 1 study reported both clinical and preclinical data, 3 studies reported preclinical data, and 18 studies reported efficacy and effectiveness outcomes in 8910 patients treated with TNFis. Clinical endpoints, such as the Clinical Disease Activity Index, the Simple Disease Activity Index, the Disease Activity Score-28 with C-reactive protein (DAS28-CRP), or erythrocyte sedimentation rate (DAS28-ESR), and Boolean remission were similar or slightly better in patients with high RF who received Fc-free TNFis, relative to those with low RF levels. CONCLUSIONS: Considering these observations, Fc-free TNFis may provide some advantages to RA patients with high RF levels.
引用
- Smolen J, Nikiphorou E, Pope J, et al. Preclinical and clinical outcomes in patients with high rheumatoid factor levels treated with TNF inhibitors:a systematic review. Ann Rheum Dis. 2026. PMID: 42833948. doi:10.1016/j.ard.2026.08.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。